ELTX
Elicio Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$189.91M
P/E Ratio
—
EPS
$-2.36
Beta
1.45
52W High
$14.93
52W Low
$5.80
50-Day MA
$10.95
200-Day MA
$9.91
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Elicio Therapeutics Inc.
Elicio Therapeutics Inc. (ELTX) is a pioneering clinical-stage biotechnology company focused on developing advanced immunotherapy treatments for cancer. Central to its innovative pipeline is the proprietary Amphiphilic TLR9 Agonist, Eli-002, which aims to elicit robust immune responses across multiple cancer types, thereby enhancing patient outcomes. By concentrating on personalized cancer vaccines and state-of-the-art immunotherapeutic approaches, Elicio is strategically positioned to tackle significant unmet medical needs in oncology and is actively progressing its clinical trials to transform cancer treatment paradigms.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-37.38M |
| Operating Margin | 0.00% |
| Return on Equity | -1076.00% |
| Return on Assets | -92.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.08 |
| Price-to-Book | 132.74 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $19.09M |
| Float | $13.19M |
| % Insiders | 29.76% |
| % Institutions | 16.99% |
Historical Volatility
HV 10-Day
130.48%
HV 20-Day
95.20%
HV 30-Day
93.96%
HV 60-Day
89.50%
HV Rank
86.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($17.50 target)
2
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026